Serologicals announced that Celliance, its wholly-owned subsidiary, has introduced Onco-Cyte cell culture product, the second addition to Ex-Cyte family of products
Onco-Cyte is a serum-free, ready-to-use formulation that replaces Fetal Bovine Serum (FBS) in suspension culture for a variety of cancer cell lines in research and bioprocessing applications.
Onco-Cyte is the second product to be added to the Ex-Cyte family of products.
Ex-Cyte is the largest selling serum-free cell culture supplement.
Hybri-Ex-Cyte, launched in February 2005, was the first in a new line of serum-free cell culture supplements in the Ex-cyte product line.
Onco-cyte is an easy-to-use product that will completely replace FBS and is optimized for specific cell lines.
It matches the performance of FBS for cancer cells grown in suspension and eliminates some of the challenges associated with FBS, such as lot-to-lot variability, validating, sourcing and multiple-lot storing.
"Cancer cell lines are widely used by academic research laboratories and companies developing cancer therapeutic products," said David Bellitt, president of Celliance.
"We think there is great market potential for FBS replacement in cancer cell lines.
"We are excited about the sales opportunities for Onco-cyte".
Onco-cyte contains several of Celliance's leading products including Ex-cyte, the largest serum-free cell culture supplement, Incelligent recombinant human insulin, and Probumin media grade bovine serum albumin.
Additional formulations for CHO, HEK293, and NSO cell lines are in the final development stage.
Serologicals has patents pending on all formulations of the Ex-cyte family of products.
